GlassScriptPhysician profile
Nicholas D Bottaro
NPI 1396193611
$5,517.92
in general payments reported to CMS, 2019-2025
24 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.78 · 2020: $175 · 2021: $709 · 2022: $580 · 2023: $662 · 2024: $2,712 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450 · Consulting Fee: $1,500 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.34 |
| Consulting Fee | $1,500.00 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,827.72 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $559.25 | 2020-2025 | Argos, Rocklatan, Simbrinza |
| Horizon Therapeutics Plc | $381.12 | 2020-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $373.56 | 2021-2025 | Cequa |
| Abbvie INC. | $355.43 | 2022-2025 | |
| Glaukos Corporation | $307.37 | 2021-2025 | Idose, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $294.07 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Allergan, INC. | $276.79 | 2020-2022 | |
| Rxsight INC | $190.73 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Kala Pharmaceuticals, INC. | $182.18 | 2021-2022 | |
| Sight Sciences, INC. | $155.27 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Biotissue Holdings INC. | $134.57 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $116.16 | 2024-2025 | Purified Cortrophin Gel |
| Dompe US, INC. | $63.39 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $53.98 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.81 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.21 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $33.26 | 2019 | |
| Apellis Pharmaceuticals, INC. | $26.66 | 2025 | Syfovre |
| New World Medical,INC. | $21.09 | 2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Oyster Point Pharma, INC. | $20.48 | 2022 | |
| Ivantis, INC | $17.08 | 2021 | |
| Amgen INC. | $17.02 | 2025 | Tepezza |
| Thrombogenics, INC. | $16.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Bottaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.